key: cord-0741885-vr484pde
authors: Tsankov, Boyan K.; Allaire, Joannie M.; Irvine, Michael A.; Lopez, Alison A.; Sauvé, Laura J.; Vallance, Bruce A.; Jacobson, Kevan
title: Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis
date: 2020-11-20
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.11.163
sha: 7a6a60075e4df28e604d2f5857ecf0de076d0463
doc_id: 741885
cord_uid: vr484pde

OBJECTIVE: There is limited information on the severity of COVID-19 infection in children with comorbidities. We investigated the effects of pediatric comorbidities on COVID-19 severity by means of a systematic review and meta-analysis of published literature. METHODS: PubMed, Embase, and Medline databases were searched for publications on pediatric COVID-19 infections published January 1(st) to October 5(th), 2020. Articles describing at least one child with and without comorbidities, COVID-19 infection, and reported outcomes, were included. RESULTS: 42 studies containing 275,661 children without comorbidities and 9,353 children with comorbidities were included. Severe COVID-19 was present in 5.1% of children with comorbidities, and in 0.2% without comorbidities. Random-effects analysis revealed a higher risk of severe COVID-19 among children with comorbidities than for healthy children; relative risk ratio 1.79 (95% CI 1.27 – 2.51;I(2) = 94%). Children with underlying conditions also had a higher risk of COVID-19-associated mortality; relative risk ratio 2.81 (95% CI 1.31 – 6.02; I(2) = 82%). Children with obesity had a relative risk ratio of 2.87 (95% CI 1.16 – 7.07 I(2) = 36%). CONCLUSIONS: Children with comorbidities have a higher risk of severe COVID-19 and associated mortality than children without underlying disease. Additional studies are required to further evaluate this relationship.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the human coronavirus disease 2019 pandemic that officially began on March 11, 2020 (Cucinotta and Vanelli, 2020) . At the time of writing of this report -November 9 th , 2020there had been 50,539,082 confirmed cases with an associated 1,258,321 deaths worldwide resulting from COVID-19 infection (COVID-19 Map, 2020) . The virus primarily affects the lower respiratory tract, and infected individuals primarily present with fever, cough, and dyspnea, however gastrointestinal (GI) manifestations can also occur Shi et al., 2020) .

Although the infection course is usually non-fatal, severe COVID-19 infection with lifethreatening presentations of acute respiratory distress syndrome (ARDS) and multiple organ failure can occur Zhou et al., 2020) . Risk factors for severe manifestations of SARS-CoV-2 illness and associated mortality include age greater than 65 years (Wu et al., 2020; Du et al., 2020) , and underlying comorbidities such as diabetes, hypertension, and obesity (Caussy et al., 2020; Du et al., 2020; Guan et al., 2020; Wu and McGoogan, 2020) .

Multiple studies on COVID-19 infection in children have noted differences in infection rates, symptoms, and mortality as compared to adults Wu et al., 2020) . One of the most comprehensive early studies of pediatric patients with SARS-CoV-2 infection reported that children develop a relatively mild disease course with 83% of confirmed cases presenting with mild to moderate infection, with an additional 13% being asymptomatic, and only 3% presenting with severe and critical illness . However, such early case series potentially suffer from decreased testing of mildly infected individuals thereby leading to a potentially low rate of documented asymptomatic infections. A recent outbreak in a children's overnight camp in the United States reported an asymptomatic infection rate of 26% among COVID-19 infected J o u r n a l P r e -p r o o f children (Szablewski, 2020) . Nonetheless, the disease course in children can be heterogenous in nature, with the most common clinical signs and symptoms including fever, headaches, and sore throat (Szablewski, 2020) . Critical illness in children and adults alike typically manifests with severe pneumonia characterized by specific oxygen concentrations less than 92%, autoinflammatory shock, and respiratory distress (Sankar et al., 2020) . Such cases frequently require mechanical ventilation and treatment with antiviral and immunomodulating regimens (Sankar et al., 2020; Zimmermann and Curtis, 2020) .

Even so, previous reports have indicated clusters of an inflammatory syndrome, called "Multisystem Inflammatory Syndrome associated with COVID-19 (MIS-C)" or "Paediatric inflammatory multisystem syndrome (PIMS)" Kawasaki-like disease, a potentially fatal vasculitis, occurring in children following COVID-19 infection (Dufort et al. 2020; Riollano-Cruz et al. 2020; . Such reports indicate the potential (albeit uncommon) for severe and potentially fatal COVID-19 in pediatric patients. Although previous studies have established preexisting comorbidities as significant risk factors for severe SARS-CoV-2 infection in adults (Du et al., 2020; Guan et al., 2020) , questions remain regarding childhood comorbidities and associated COVID-19 outcomes. While systematic reviews and meta-analyses examining COVID-19 in pediatric patients have been published (Ding, Yan, and Guo, 2020; Hoang et al. 2020) , these reports did not evaluate the risk of severe SARS-CoV-2 infection specifically in children with preexisting conditions. Consequently, the objective of this systematic review and meta-analysis is to examine the relative risk of severe COVID-19 infection and associated mortality in children with comorbidities.

For this systematic review and meta-analysis PubMed, Medline, and Embase databases were queried for articles published between January 1 st , 2020 until October 5 th , 2020. The Medline and Embase searches were conducted via the Ovid interface. The search terms "COVID-19", "SARS-nCoV-2", "SARS-CoV-2", "2019-nCoV", "novel coronavirus", and "coronavirus" were used to obtain articles relating to the novel coronavirus pandemic occurring in 2020. To obtain literature pertaining specifically to SARS-CoV-2 infection in pediatric patients, the terms "child*", "pediatr*", "paediatr*", "teenage", "adolescent", "infant", and "newborn" were queried in conjunction with the coronavirus search. For the full search queries, see Supplement S1. To capture articles potentially missed by our systematic search, Google Scholar was queried for articles pertaining to COVID-19 infection in pediatric patients. Further articles were obtained by examining the references of highly relevant systematically retrieved articles. Only articles in English were considered for inclusion. References were managed with Endnote (version X9.0) software which was also used for duplicate removal. The systematic literature search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) recommendations (Moher et al., 2009) .

Following deduplication, the reference titles were reviewed by BKT. Titles that did not imply a subject matter relevant to COVID-19 in pediatric patients were excluded. Following title review, the full-text content of the remaining literature was thoroughly analyzed by the author BKT. The following exclusion criteria were applied to the full-text articles: articles not mentioning pediatric comorbidities; adult only studies; articles where the pediatric comorbidity data was indistinguishable from adult comorbidity data; pre-existing reviews, systematic-reviews, and J o u r n a l P r e -p r o o f meta-analyses; articles with patients without confirmed COVID-19 infections; basic science studies; clinical discussions, recommendations, and guidelines; articles without reported patient outcomes; and studies of other coronaviruses. Articles containing at least one paediatric patient with comorbidities, and one paediatric patient without comorbidities were included. Furthermore, we included articles for which the severity and outcomes of SARS-CoV-2 infection in the paediatric patients was clearly defined. Following full-text review, BKT and KJ graded the remaining studies using the National Institutes of Health (NIH) Quality Assessment Tool for Case Series and Studies (Study Quality Assessment Tools, NHLBI, NIH). Any disagreements in rating were handled via discussion by the two reviewers until a consensus was reached. For the literature grading see Supplement S2.

The study authors; design; country of origin; aims; pediatric sample size; COVID-19 infection counts; disease severity; comorbidity counts; pediatric intensive care unit (PICU) admittance counts; and mortality counts were extracted from the included literature. The extracted comorbidities were either defined by the studies or classified into representative broader categories by BKT and KJ. Comorbidities such as trisomy 21, prematurity, and undefined genetic abnormalities were deemed as "other" pre-existing conditions. Obesity was defined by the studies where available, or by the authors as a body mass index (BMI) at or greater than the 95 th percentile for children of the same age and sex according to CDC definitions (Defining Childhood Obesity, 2019). To operationalize severe COVID-19 infection across the different studies, severe infection was deemed as any SARS-CoV-2 infection requiring supplemental help to normal breathing and/or J o u r n a l P r e -p r o o f admission to a PICU unless otherwise explicitly stated in the literature. Finally, paediatric patients were defined as participants suffering from COVID-19 who were below 21 years of age.

PICU admission and mortality outcomes were assessed using a random effects metaanalysis (Schwarzer, Carpenter, and Rücker 2015) . A random effects model was chosen due to the potential variation in sampled study populations leading to differences in outcomes by comorbidities. Estimation of random-effects variance was conducted using the Sidik-Jonkman estimator with Hartung-Knapp adjustment (IntHout, Ioannidis, and Borm 2014). For individual trials with no events in one or both groups, a continuity correction of the opposite treatment arm size was added to each cell for each effect measure (Sweeting et al., 2004) . Binary estimators including risk ratios, and risk difference were estimated using the Mantel-Haenszel method (Mantel and Haenszel 1959; Robins, Breslow, and Greenland 1986) There were 13310 studies identified from our systematic search across the three databases ( Figure   1 ). Following de-duplication, 8206 records were reviewed based on a title screen, of which 7398 were deemed irrelevant to the subject matter of this study. The full-texts of the remaining 808 articles were reviewed for the presence of pediatric study participants who had: 1) pre-existing comorbidities; and 2) COVID-19 infection, for which clear outcomes were reported. 98 articles then underwent literature grading, with 86 studies deemed fair for further analysis. Among these 86 articles, only 42 had pediatric case-control participants without comorbidities with either severe COVID-19 and/or COVID-19-associated mortality. Five studies (Bellino et al., 2020; Bixler et al., 2020; Blumfield et al., 2020; Moraleda et al., 2020; Otto et al., 2020) only examined children who died from COVID-19 and were therefore only included in the mortality analysis. These 42 studies were therefore the basis for our analysis examining the effects of comorbidities on severe and potentially fatal manifestations of pediatric SARS-CoV-2 infection. Among the 42 articles, 18 studies were from the USA (43%), and 4 studies were from China (10%), Italy (10%), and Spain (10%) respectively. Of the remaining studies, 3 were from France (7%), 2 were from the United Kingdom (5%), and Iran (5%), and 1 was from Austria (2%), Brazil (2%), India (2%), Turkey (2%), and Uruguay (2%) ( Table 1) .

From the 42 articles, a total of 285,004 pediatric patients with laboratory-confirmed SARS-CoV-2 infection were identified. Among this cohort, 9,353 (3.3%) had at least one underlying comorbidity (Table 1) . Gender demographic data was available for 280,999 COVID-19 infected children, of which 142,411 (50.7%) were female and 138,588 (49.3%) were male. We were able to extrapolate age-category data in 362 children. Of these, 138 (38%) were under 1 year of age, 82 J o u r n a l P r e -p r o o f (21%) 1 to 5 years of age, 31 (8%) 6 to 10, 22 (6%) 10 -14, and 89 (23%) were older than 14 years of age. To the best of our ability, we have excluded any study participants that were over 21 years, such as those present in the study by DeBiasi and colleagues.

Among the 9,353 pediatric patients with SARS-CoV-2 infection and underlying comorbidities, 481 (5.1%) had severe COVID-19 and/or were admitted to a PICU (Table 1 ). In contrast, only 579 of the 275,661 (0.21%) pooled pediatric patients without comorbidities had a severe manifestation of COVID-19. Employing a random-effects model to examine the relative risk of severe COVID-

Nineteen of the 42 articles included in this meta-analysis reported children who died while being infected with SARS-CoV-2 ( Figure 4 ). Across the 19 articles, of the 274,647 pediatric patients without comorbidities and COVID-19 infection, only 77 (0.03%) died across 8 studies (Bixler et al., 2020; Cai et al., 2020; Du et al., 2020; Götzinger et al., 2020; Leeb et al., 2020; Oualha et al., 2020; Riollano-Cruz et al., 2020; Yayla et al., 2020) . In contrast, 134 (1.5%) of the 8960 children with pre-existing conditions died during the course of their SARS-CoV-2 infection across 15 studies (Bellino et al., 2020; Bixler et al., 2020; Blumfield and Levin, 2020; Chao et al., 2020 , de Farias et al., 2020 Derespina et al., 2020; Diorio et al., 2020; Eghbali et al., 2020; Götzinger et al., 2020; Kainth et al., 2020; Leeb et al., 2020; Moraleda et al., 2020; Otto et al., 2020 , Oualha et al., 2020 Swann et al., 2020) (Table 1) . The random effects model used to determine the risk of mortality among children with comorbidities and COVID-19 relative to pediatric patients without comorbidities revealed a total risk ratio of 2.81 (95% CI 1.31 -6.02; 2 = 97.85 (P < 0.001); I 2 = 82%) (Figure 4) . In only five of the studies (Cai et al., 2020; Du et al., 2020; Oualha et al., 2020; Riollano-Cruz et al., 2020; Yayla et al., 2020 ) did children with comorbidities have a lower risk of mortality during the course of COVID-19 ( Figure 4) . Notably, subsequent sensitivity analysis confirmed that no one article significantly affected the relative risk ratio of mortality among children with pre-existing conditions ( Figure 5 ).

Our previously presented analyses hinted at a higher risk of severe COVID-19 infection and associated mortality among pediatric patients with underlying comorbidities (Figures 2 and 4) . We J o u r n a l P r e -p r o o f next sought to examine the potential impact of specific comorbidities on the risks of severe SARS-CoV-2 manifestations. For details on the underlying conditions represented among all 9, 353 children with comorbidities regardless of COVID-19 severity, see Supplement S3. In the 42 studies included in this meta-analysis, we found that among children with severe COVID-19, 64 children were obese (Abdel-Mannan et al., 2020; Chao et al., 2020; de Farias et al., 2020; DeBiasi et al., 2020; Derespina et al., 2020; Giacomet et al., 2020; Gonzalez-Dambrauskas et al., 2020; Kaushik et al., 2020; Lovinsky-Desir et al., 2020; Shekerdemian et al., 2020; Swann et al., 2020; Waltuch et al., 2020; Zachariah et al., 2020) , 58 had chronic respiratory disease (Belhadjer et al., 2020; Chao et al., 2020; DeBiasi et al., 2020; Diorio et al., 2020; Gonzalez-Dambrauskas et al., 2020 , Götzinger et al., 2020 Lovinsky-Desir et al., 2020; Mannheim et al., 2020; Riollano-Cruz et al., 2020; Shekerdemian et al., 2020; Swann et al., 2020; Waltuch et al., 2020; Yayla et al., 2020; Zachariah et al., 2020) , 45 had cardiovascular disease (Chao et al., 2020; DeBiasi et al., 2020; Derespina et al., 2020; Diorio et al., 2020; Eghbali et al., 2020; Garazzino et al., 2020; Giacomet et al., 2020; Gonzalez-Dambrauskas et al., 2020; Götzinger et al., 2020; Kainth et al., 2020; Kaushik et al., 2020; Mannheim et al.; , Schwartz et al., 2020 Shekerdemian et al., 2020; Swann et al., 2020; Zachariah et al., 2020; Zheng et al., 2020) , 33 had neurologic disorders (Cai et al., 2020; Chao et al., 2020; DeBiasi et al., 2020; Diorio et (Eghbali et al., 2020; Garcia-Salido et al., 2020; Kaushik et al., 2020; Oualha et al., 2020; Shekerdemian et al., 2020; Yayla et al., 2020; Zachariah et al., 2020) , and 11 had cancer (Chao et al., 2020; Diorio et al., 2020; Kainth et al., 2020; Du et al., 2020; Gonzalez-Dambrauskas et al., 2020; Götzinger et al., 2020; Sun et al., 2020) . Five children had renal disease (Cai et al., 2020; Götzinger et al., 2020; Oualha et al., 2020) , and 2 had GI comorbidities (Giacomet et al., 2020) respectively. Seventy-one children had other conditions (Diorio et al., 2020; Garazzino et al., 2020; Gonzalez-Dambrauskas et al., 2020; Götzinger et al., 2020; Kainth et al., 2020; Mannheim et al., 2020; Schwartz et al., 2020; Shekerdemian et al., 2020; Swann et al., 2020; Zachariah et al., 2020) including prematurity, trisomy 21, or other genetic abnormalities. Finally, only 1 child presented with allergies (Du et al., 2020) and hepatobiliary disease (Riollano-Cruz et al., 2020) respectively. We next analyzed the relative contribution of childhood obesity to pediatric COVID-19 severity.

We chose to focus primarily on obesity as it has an easily definable metric (i.e. BMI) that can be compared across multiple studies. Although 64 pediatric patients with underlying obesity presented with severe COVID-19 across 13 studies (Abdel-Mannan et al., 2020; Chao et al., 2020; de Farias et al., 2020; DeBiasi et al., 2020; Derespina et al., 2020; Giacomet et al., 2020; Gonzalez-Dambrauskas et al., 2020; Kaushik et al., 2020; Lovinsky-Desir et al., 2020; Shekerdemian et al., 2020; Swann et al., 2020; Waltuch et al., 2020; Zachariah et al., 2020) , we chose to perform a meta-analysis only on the studies that included case-control participants (Abdel-Mannan et al., 2020; Chao et al., 2020; Giacomet et al., 2020; Moreno-Galarraga et al., 2020; Swann et al., 2020; Zachariah et al., 2020) . Examining the risk of obesity on COVID-19 severity in relation to children without comorbidities and SARS-CoV-2 infection, we obtained a relative risk ratio of 2.87 (95% J o u r n a l P r e -p r o o f 14 CI 1.16 -7.07; 2 = 7.81 (P = 0.17); I 2 = 36%) ( Figure 6 ). We also examined the relative risk of childhood cancer on severe COVID-19 (Supplement S4), from which we were not able to draw any conclusions due to the confidence interval of the relative risk ratio spanning a value of 1.0.

Taken together, these results indicate that childhood obesity likely increases risk of severe COVID-19. However, more case-controlled, well-defined studies are needed to examine the effects that other childhood comorbidities such as cancer have on risk of severe manifestations of SARS-CoV-2.

examine the overall characteristics, symptoms, and outcomes of SARS-CoV-2 infection regardless of comorbidity status (Ding et al., 2020; Hoang et al., 2020; Ludvigsson, 2020) . Studies suggest that children typically have a milder infection course than adults, with an overall good prognosis.

However, the effects of comorbidities on COVID-19 severity in children remain unclear. Although a previous correspondence suggested a worse SARS-CoV-2 infection course in children with comorbidities (Harman et al., 2020) , the small sample size precludes definitive conclusions. In this systematic review and meta-analysis of 42 articles, we report that children with comorbidities are at higher risk for severe manifestations of COVID-19 and associated mortality relative to previously healthy children. Furthermore, we also note that childhood obesity probably leads to a worse COVID-19 prognosis. To our knowledge, we are the first to report these findings.

Early analyses in adults with COVID-19 indicated that older age (Zhou et al., 2020) and comorbidities such as diabetes, hypertension, malignancies, chronic respiratory disease and J o u r n a l P r e -p r o o f obesity are significant risk factors for severe infection (Caussy et al., 2020; Guan et al., 2020; Yang et al., 2020) . As such, the early lockdown measures implemented across the world in the spring of 2020 were aimed at protecting vulnerable populations (i.e., the elderly and people with comorbid conditions) from COVID-19 infection, as well as preventing the overburdening of hospitals. In contrast, early epidemiological studies of pediatric populations cited high mild and asymptomatic COVID-19 infection rates, with certain publications advocating for their return to school (Munro and Faust, 2020; van Bruwaene et al., 2020) . The results from our study suggest that children with specific comorbidities are a vulnerable population at high risk for potentially life-threatening consequences of COVID-19 infection.

We report that childhood obesity is likely associated with a worsened prognosis of infection. This is in keeping with several adult studies that note that patients who had a BMI greater than or equal to 35kg/m 2 required invasive mechanical ventilation due to SARS-CoV-2 infection more frequently than their leaner counterparts (Caussy et al., 2020; Simmonet et al., 2020) . The effects of childhood obesity in potentiating severe COVID-19 are unsurprising. The high visceral adiposity present in obese individuals is known to induce higher levels of local and systemic inflammatory cytokines such as Interleukin-6 (IL-6), and C-reactive protein (CRP) (Fontana et al., 2007) . The baseline increases in these cytokines in obesity are also likely the result of increased pro-inflammatory macrophage populations that have been observed in this population (Russo and Lumeng, 2018) . These cytokines have been positively correlated with COVID-19 severity (Zeng et al., 2020) and their higher baseline levels in obese individuals may contribute to their increased susceptibility to severe infection. However, childhood obesity likely contributes to severe COVID-19 infection in additional ways.

Unfortunately, we were unable to determine whether other comorbidities such as childhood cancer increases risk of severe COVID-19. This is in part due to the paucity of case-controlled literature examining the outcomes of children with COVID-19 who have well-defined comorbid conditions. Towards this aim, various international Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE) databases and registries are set up to prospectively collect data, and will be particularly helpful in defining risk of COVID-19 infection and severity in patients with comorbidities. However, to date the available data remain quite limited. Apart from a recent article (Brenner et al., 2020) and the SECURE-IBD database (SECURE-IBD Database), a multi-national database examining the outcomes of patients with IBD and COVID-19, limited literature examining the effects of GI diseases on COVID-19 outcomes in children has been published. Furthermore, although recent approaches have begun examining the effects of COVID-19 infection on diseases such as sickle-cell disease (SSD) (McCloskey et al., 2020; Hussain et al., 2020) , limited data exists for other systemic diseases. For example, for rheumatic diseases, apart from a retrospective report (Zhong et al., 2020) , only a speculative review on the topic has been published (Licciardi et al., 2020) . With reports of MIS-C occurring in cohorts of children with COVID-19 infection (Davies and Evans, 2020; Riphagen et al., 2020; the dynamics and underlying characteristics of severe infection in the context of autoinflammatory comorbidities in children require further study.

Our study has several important strengths. To our knowledge, this is the first systematic review and meta-analysis that examines the relative risk of severe COVID-19 and associated mortality J o u r n a l P r e -p r o o f among children with comorbidities. Furthermore, our study is the first to show that childhood obesity likely increases the risk of severe COVID-19 infection course. Lastly, our study has a relatively large sample size of 9,353 children with comorbidities among 42 articles. This relatively large sample size and study number allows for high statistical power which allows for accurate conclusions to be drawn based on the study results.

Our systematic review and meta-analysis have several potential limitations. Most importantly, there likely exists variations in PICU admission criteria across the studies, particularly regarding children with comorbidities and COVID-19 infection. We cannot ascertain whether admission to the PICU was primarily due to problems with underlying comorbidities in some children, with COVID-19 infection being subsequently discovered. Therefore, the increased risk of severe COVID-19 infection among children with comorbidities addressed in this meta-analysis could be the result of a selection bias of PICU admission in favor of children with underlying conditions. Furthermore, our study is subject to a high degree of study heterogeneity due to the small sample size of some of the included studies. In addition, based on the large body of rapidly-published literature surrounding COVID-19 infection, some studies may have used similar participants. Therefore, we cannot be certain that patients were not duplicated in our study. Our meta-analysis was also not able to capture the relative risk that comorbidities other than obesity contribute to severe SARS-CoV-2 viral infection. This is due to the sub-population heterogeneity of comorbidities that limits the ability to draw accurate comparisons between the studies. Lastly, our meta-analysis amplifies the ascertainment bias of the primary literature. Asymptomatic COVID-19 infections among children with comorbidities do occur (Poli et al., 2020) , however in most jurisdictions at this time, testing of asymptomatic or pauci-symptomatic children is very limited outside of outbreak settings. Consequently, such mild cases among children with comorbidities are likely less represented in the primary literature and therefore in our analysis. We therefore call for further availability of data on pediatric patients with comorbidities and COVID-19 outcomes, regardless of illness severity. Such broader representation within the literature would increase the accuracy of relative risk computation within this population by future meta-analyses.

To our knowledge, this is the first systematic review and meta-analysis examining the severity of COVID-19 infection among pediatric patients with comorbidities. We report that children with pre-existing conditions are at a greater risk of severe COVID-19 and associated mortality. In particular, childhood obesity is likely positively correlated with COVID-19 severity. However, further cross-sectional, case-controlled studies examining the effects of specific well-defined comorbidities are required to examine the effects that pediatric underlying conditions play in COVID-19 severity. 

Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children

Clinical profile, viral load, management and outcome of neonates born to COVID 19 positive mothers: a tertiary care centre experience from India

How to perform a meta-analysis with R: a practical tutorial

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic

COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy

Clinical Features of Critical Coronavirus Disease 2019 in Children

Imaging of children with COVID-19: experience from a tertiary children's hospital in the United States

SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years -United States

COVID-19 in pediatric patients: a case series from the Bronx, NY

But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Clinical Characteristics of 5 COVID-19 Cases With Nonrespiratory Symptoms as the First Manifestation in Children

Obesity is Associated with Severe Forms of COVID-19

Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center

WHO Declares COVID-19 a Pandemic

Multisystem Inflammatory Syndrome Associated With Coronavirus Disease in Children: A Multicentered Study in Belém

Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region

Clinical Manifestations and Outcomes of Critically Ill Children and Adolescents with Coronavirus Disease

Clinical Characteristics of Children With COVID-19: A Meta-Analysis. Front Pediatr 2020

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

Epidemiology of COVID-19 Among Children in China

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

COVID-19 in pediatric patients: A case series

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10

Children in Critical Care Due to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Experience in a Spanish Hospital

Gastrointestinal Symptoms in Severe COVID-19 Children

Pediatric Critical Care and COVID-19

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Ethnicity and COVID-19 in children with comorbidities

COVID-19 in 7780 pediatric patients: A systematic review

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 infection in patients with sickle cell disease

Early Experience of COVID-19 in a US Children's Hospital

Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City

COVID-19 Trends Among School-Aged Children -United States

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country

Asthma among hospitalized patients with COVID-19 and related outcomes

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Characteristics of Hospitalized Pediatric Coronavirus Disease

Statistical aspects of the analysis of data from retrospective studies of disease

COVID-19 infection and sickle cell disease: a UK centre experience

Coronavirus Disease 2019 in Newborns and Very Young Infants: a Series of Six Patients in France

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain

SARS-CoV-2 infection in children requiring hospitalization: the experience of Navarra

Children are not COVID-19 super spreaders: time to go back to school

The Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Healthcare Network in the United States

Severe and fatal forms of COVID-19 in children

COVID-19 in 17 Italian Pediatric Emergency Departments

Multisystem inflammatory syndrome in children related to COVID-19: A New York City experience

Hyperinflammatory shock in children during COVID-19 pandemic

Estimators of the Mantel-Haenszel Variance Consistent in Both Sparse Data and Large-Strata Limiting Models

Properties and functions of adipose tissue macrophages in obesity

COVID-19 in Children: Clinical Approach and Management

Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes

Meta-Analysis with R

Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp -Georgia

Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in

R: A Language and Environment for Statistical Computing

What are we doing to the children of South Africa under the guise of COVID-19 lockdown?

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Features of COVID-19 postinfectious cytokine release syndrome in children presenting to the emergency department

Welcome to the Tidyverse

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Characteristics and Management of Children with COVID-19 in Turkey

Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in

Association of inflammatory markers with the severity of COVID-19: A meta-analysis

Clinical Characteristics of Children with Coronavirus Disease

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children